Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MGX | Common Stock | Conversion of derivative security | +1.77M | 1.77M | Feb 13, 2024 | Direct | F1, F2 | |||
transaction | MGX | Common Stock | Conversion of derivative security | +1.18M | +66.67% | 2.95M | Feb 13, 2024 | Direct | F2, F3 | ||
transaction | MGX | Common Stock | Conversion of derivative security | +590K | +19.98% | 3.54M | Feb 13, 2024 | Direct | F2, F4 | ||
transaction | MGX | Common Stock | Conversion of derivative security | +510K | +14.4% | 4.05M | Feb 13, 2024 | Direct | F2, F5 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | MGX | Series A-1 Convertible Preferred Stock | Conversion of derivative security | $0 | -3.09M | -100% | $0.00* | 0 | Feb 13, 2024 | Common Stock | 1.77M | Direct | F1, F2 | |
transaction | MGX | Series A-4 Convertible Preferred Stock | Conversion of derivative security | $0 | -2.06M | -100% | $0.00* | 0 | Feb 13, 2024 | Common Stock | 1.18M | Direct | F2, F3 | |
transaction | MGX | Series B Convertible Preferred Stock | Conversion of derivative security | $0 | -1.03M | -100% | $0.00* | 0 | Feb 13, 2024 | Common Stock | 590K | Direct | F2, F4 | |
transaction | MGX | Series B-1 Convertible Preferred Stock | Conversion of derivative security | $0 | -891K | -100% | $0.00* | 0 | Feb 13, 2024 | Common Stock | 510K | Direct | F2, F5 |
Id | Content |
---|---|
F1 | Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering ("IPO"). |
F2 | The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP ("BUSH LP"), a Delaware limited partnership. Bayer World Investments B.V. ("BWI"), a Dutch private limited company, is the general partner of BUSH LP. BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC. |
F3 | Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. |
F4 | Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. |
F5 | Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO. |